| Ytd | 218.34% | |
| 1y | 328.96% |
| Open | 11.10 | Prev Close | 11.59 | Low | 10.82 | High | 11.69 | Mkt Cap | 1.88B |
| Vol | 5.08M | Avg Vol | 5.92M | EPS | -0.82 | P/E | N/A | Forward P/E | -18.18 |
| Beta | 2.46 | Short Ratio | 7.08 | Inst. Own | 72.91% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 6.38 | 200-d Avg | 4.01 | 1yr Est | 12.40 |
ABSI News
Anthropic launches Claude Science for researchers as PwC data shows AI mentions in pharma M&A de
Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pha
Top analysts changed outlook on top names. See full changes, upgrades, downgrades on analyst ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Absci (NASDAQ:ABSI) with a Buy a
ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The
Gainers Pulsenmore (NASDAQ:PLSM) shares moved upwards by 160.5% to $8.88 during Wednesday's reg
U.S. stocks rose, with Nasdaq up 50 points. KB Home (NYSE: KBH) reported strong Q2 results, shares j
Absci reported positive interim Phase 1 ABS-201 data and priced a $100 million stock offering to adv
Gainers Pulsenmore (NASDAQ:PLSM) stock increased by 152.0% to $8.59 during Wednesday's pre-mark
The gross proceeds from the offering, before deducting underwriting discounts and commissions and of
Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of t
Guggenheim analyst Vamil Divan maintains Absci (NASDAQ:ABSI) with a Buy and raises the price targ
Stocks had mixed performance on Thursday, Dow Jones up 793 points while Nasdaq down 232 points. Rumb
Leerink Partners analyst Mani Foroohar initiates coverage on Absci (NASDAQ:ABSI) with a Outperfor